SrasV1, PubMed, Checkpoint, bibRecord, 001858

Individual and common inhibitors of coronavirus and picornavirus main proteases.

Identifieur interne : 001858 ( PubMed/Checkpoint ); précédent : 001857; suivant : 001859

Individual and common inhibitors of coronavirus and picornavirus main proteases.

Auteurs : Chih-Jung Kuo [République populaire de Chine] ; Hun-Ge Liu ; Yueh-Kuei Lo ; Churl-Min Seong ; Kee-In Lee ; Young-Sik Jung ; Po-Huang Liang

Source :

FEBS letters [ 1873-3468 ] ; 2009.

RBID : pubmed:19166843

Descripteurs français

English descriptors

KwdEn :
- Amino Acid Sequence, Computer Simulation, Conserved Sequence, Coronavirus (drug effects), Coronavirus (enzymology), Drug Evaluation, Preclinical, Models, Molecular, Molecular Sequence Data, Peptide Hydrolases (chemistry), Peptide Hydrolases (metabolism), Picornaviridae (drug effects), Picornaviridae (enzymology), Protease Inhibitors (chemistry), Protease Inhibitors (pharmacology), Protein Binding, Protein Structure, Tertiary, Sequence Alignment, Structure-Activity Relationship.
MESH :
- chemical , chemistry : Peptide Hydrolases, Protease Inhibitors.
- drug effects : Coronavirus, Picornaviridae.
- enzymology : Coronavirus, Picornaviridae.
- chemical , metabolism : Peptide Hydrolases.
- chemical , pharmacology : Protease Inhibitors.
- Amino Acid Sequence, Computer Simulation, Conserved Sequence, Drug Evaluation, Preclinical, Models, Molecular, Molecular Sequence Data, Protein Binding, Protein Structure, Tertiary, Sequence Alignment, Structure-Activity Relationship.

Abstract

Picornaviruses (PV) and coronaviruses (CoV) are positive-stranded RNA viruses which infect millions of people worldwide each year, resulting in a wide range of clinical outcomes. As reported in this study, using high throughput screening against approximately 6800 small molecules, we have identified several novel inhibitors of SARS-CoV 3CL(pro) with IC(50) of low microM. Interestingly, one of them equally inhibited both 3C(pro) and 3CL(pro) from PV and CoV, respectively. Using computer modeling, the structural features of these compounds as individual and common protease inhibitors were elucidated to enhance our knowledge for developing anti-viral agents against PV and CoV.

DOI: 10.1016/j.febslet.2008.12.059
PubMed: 19166843

Affiliations:

République populaire de Chine

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 001974
to stream PubMed, to step Curation: 001974

Links to Exploration step

pubmed:19166843

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Individual and common inhibitors of coronavirus and picornavirus main proteases.</title>
<author><name sortKey="Kuo, Chih Jung" sort="Kuo, Chih Jung" uniqKey="Kuo C" first="Chih-Jung" last="Kuo">Chih-Jung Kuo</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liu, Hun Ge" sort="Liu, Hun Ge" uniqKey="Liu H" first="Hun-Ge" last="Liu">Hun-Ge Liu</name>
</author>
<author><name sortKey="Lo, Yueh Kuei" sort="Lo, Yueh Kuei" uniqKey="Lo Y" first="Yueh-Kuei" last="Lo">Yueh-Kuei Lo</name>
</author>
<author><name sortKey="Seong, Churl Min" sort="Seong, Churl Min" uniqKey="Seong C" first="Churl-Min" last="Seong">Churl-Min Seong</name>
</author>
<author><name sortKey="Lee, Kee In" sort="Lee, Kee In" uniqKey="Lee K" first="Kee-In" last="Lee">Kee-In Lee</name>
</author>
<author><name sortKey="Jung, Young Sik" sort="Jung, Young Sik" uniqKey="Jung Y" first="Young-Sik" last="Jung">Young-Sik Jung</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19166843</idno>
<idno type="pmid">19166843</idno>
<idno type="doi">10.1016/j.febslet.2008.12.059</idno>
<idno type="wicri:Area/PubMed/Corpus">001974</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001974</idno>
<idno type="wicri:Area/PubMed/Curation">001974</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001974</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001858</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001858</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Individual and common inhibitors of coronavirus and picornavirus main proteases.</title>
<author><name sortKey="Kuo, Chih Jung" sort="Kuo, Chih Jung" uniqKey="Kuo C" first="Chih-Jung" last="Kuo">Chih-Jung Kuo</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan, ROC.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country>
<wicri:regionArea>Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan</wicri:regionArea>
<wicri:noRegion>Taiwan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liu, Hun Ge" sort="Liu, Hun Ge" uniqKey="Liu H" first="Hun-Ge" last="Liu">Hun-Ge Liu</name>
</author>
<author><name sortKey="Lo, Yueh Kuei" sort="Lo, Yueh Kuei" uniqKey="Lo Y" first="Yueh-Kuei" last="Lo">Yueh-Kuei Lo</name>
</author>
<author><name sortKey="Seong, Churl Min" sort="Seong, Churl Min" uniqKey="Seong C" first="Churl-Min" last="Seong">Churl-Min Seong</name>
</author>
<author><name sortKey="Lee, Kee In" sort="Lee, Kee In" uniqKey="Lee K" first="Kee-In" last="Lee">Kee-In Lee</name>
</author>
<author><name sortKey="Jung, Young Sik" sort="Jung, Young Sik" uniqKey="Jung Y" first="Young-Sik" last="Jung">Young-Sik Jung</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</analytic>
<series><title level="j">FEBS letters</title>
<idno type="eISSN">1873-3468</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Computer Simulation</term>
<term>Conserved Sequence</term>
<term>Coronavirus (drug effects)</term>
<term>Coronavirus (enzymology)</term>
<term>Drug Evaluation, Preclinical</term>
<term>Models, Molecular</term>
<term>Molecular Sequence Data</term>
<term>Peptide Hydrolases (chemistry)</term>
<term>Peptide Hydrolases (metabolism)</term>
<term>Picornaviridae (drug effects)</term>
<term>Picornaviridae (enzymology)</term>
<term>Protease Inhibitors (chemistry)</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Protein Binding</term>
<term>Protein Structure, Tertiary</term>
<term>Sequence Alignment</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Alignement de séquences</term>
<term>Coronavirus ()</term>
<term>Coronavirus (enzymologie)</term>
<term>Données de séquences moléculaires</term>
<term>Inhibiteurs de protéases ()</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Liaison aux protéines</term>
<term>Modèles moléculaires</term>
<term>Peptide hydrolases ()</term>
<term>Peptide hydrolases (métabolisme)</term>
<term>Picornaviridae ()</term>
<term>Picornaviridae (enzymologie)</term>
<term>Relation structure-activité</term>
<term>Simulation numérique</term>
<term>Structure tertiaire des protéines</term>
<term>Séquence conservée</term>
<term>Séquence d'acides aminés</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Peptide Hydrolases</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term>
<term>Picornaviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Coronavirus</term>
<term>Picornaviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Coronavirus</term>
<term>Picornaviridae</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptide Hydrolases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Peptide hydrolases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Computer Simulation</term>
<term>Conserved Sequence</term>
<term>Drug Evaluation, Preclinical</term>
<term>Models, Molecular</term>
<term>Molecular Sequence Data</term>
<term>Protein Binding</term>
<term>Protein Structure, Tertiary</term>
<term>Sequence Alignment</term>
<term>Structure-Activity Relationship</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Alignement de séquences</term>
<term>Coronavirus</term>
<term>Données de séquences moléculaires</term>
<term>Inhibiteurs de protéases</term>
<term>Liaison aux protéines</term>
<term>Modèles moléculaires</term>
<term>Peptide hydrolases</term>
<term>Picornaviridae</term>
<term>Relation structure-activité</term>
<term>Simulation numérique</term>
<term>Structure tertiaire des protéines</term>
<term>Séquence conservée</term>
<term>Séquence d'acides aminés</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Picornaviruses (PV) and coronaviruses (CoV) are positive-stranded RNA viruses which infect millions of people worldwide each year, resulting in a wide range of clinical outcomes. As reported in this study, using high throughput screening against approximately 6800 small molecules, we have identified several novel inhibitors of SARS-CoV 3CL(pro) with IC(50) of low microM. Interestingly, one of them equally inhibited both 3C(pro) and 3CL(pro) from PV and CoV, respectively. Using computer modeling, the structural features of these compounds as individual and common protease inhibitors were elucidated to enhance our knowledge for developing anti-viral agents against PV and CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19166843</PMID>
<DateCompleted><Year>2009</Year>
<Month>02</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3468</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>583</Volume>
<Issue>3</Issue>
<PubDate><Year>2009</Year>
<Month>Feb</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>FEBS letters</Title>
<ISOAbbreviation>FEBS Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Individual and common inhibitors of coronavirus and picornavirus main proteases.</ArticleTitle>
<Pagination><MedlinePgn>549-55</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.febslet.2008.12.059</ELocationID>
<Abstract><AbstractText>Picornaviruses (PV) and coronaviruses (CoV) are positive-stranded RNA viruses which infect millions of people worldwide each year, resulting in a wide range of clinical outcomes. As reported in this study, using high throughput screening against approximately 6800 small molecules, we have identified several novel inhibitors of SARS-CoV 3CL(pro) with IC(50) of low microM. Interestingly, one of them equally inhibited both 3C(pro) and 3CL(pro) from PV and CoV, respectively. Using computer modeling, the structural features of these compounds as individual and common protease inhibitors were elucidated to enhance our knowledge for developing anti-viral agents against PV and CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuo</LastName>
<ForeName>Chih-Jung</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Hun-Ge</ForeName>
<Initials>HG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lo</LastName>
<ForeName>Yueh-Kuei</ForeName>
<Initials>YK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Seong</LastName>
<ForeName>Churl-Min</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Kee-In</ForeName>
<Initials>KI</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jung</LastName>
<ForeName>Young-Sik</ForeName>
<Initials>YS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liang</LastName>
<ForeName>Po-Huang</ForeName>
<Initials>PH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>01</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>FEBS Lett</MedlineTA>
<NlmUniqueID>0155157</NlmUniqueID>
<ISSNLinking>0014-5793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.-</RegistryNumber>
<NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>FEBS Lett. 2009 Jun 18;583(12):2154</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017124" MajorTopicYN="N">Conserved Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010849" MajorTopicYN="N">Picornaviridae</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>11</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>12</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>12</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>1</Month>
<Day>27</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>2</Month>
<Day>17</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19166843</ArticleId>
<ArticleId IdType="pii">S0014-5793(09)00016-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.febslet.2008.12.059</ArticleId>
<ArticleId IdType="pmc">PMC7094298</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 1998 Oct 24;352(9137):1391</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9802304</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Top Med Chem. 2006;6(4):361-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16611148</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Expert Rev Anti Infect Ther. 2006 Apr;4(2):291-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16597209</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1988 Apr;32(4):409-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2897829</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 1999 Sep 23;341(13):929-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2009 Feb 4;583(3):549-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19166843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2006 Aug 10;49(16):4971-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16884309</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2007 Jun 22;358(1):7-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17485072</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem. 2005 Sep 1;13(17):5240-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15994085</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 1974 Jul 13;2(7872):112</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4136956</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11000-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10500114</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 11;318(4):862-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15147951</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2005 Feb;49(2):619-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15673742</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2006 Sep;71(2-3):391-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16675037</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Biochem. 1988;57:701-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3052288</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem. 2008 Aug 1;16(15):7388-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18583140</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Recent Pat Antiinfect Drug Discov. 2007 Jan;2(1):1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18221160</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2005 Jan;86(Pt 1):197-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15604447</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Bioorg Med Chem. 2008 Mar 15;16(6):3091-107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18248816</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><noCountry><name sortKey="Jung, Young Sik" sort="Jung, Young Sik" uniqKey="Jung Y" first="Young-Sik" last="Jung">Young-Sik Jung</name>
<name sortKey="Lee, Kee In" sort="Lee, Kee In" uniqKey="Lee K" first="Kee-In" last="Lee">Kee-In Lee</name>
<name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
<name sortKey="Liu, Hun Ge" sort="Liu, Hun Ge" uniqKey="Liu H" first="Hun-Ge" last="Liu">Hun-Ge Liu</name>
<name sortKey="Lo, Yueh Kuei" sort="Lo, Yueh Kuei" uniqKey="Lo Y" first="Yueh-Kuei" last="Lo">Yueh-Kuei Lo</name>
<name sortKey="Seong, Churl Min" sort="Seong, Churl Min" uniqKey="Seong C" first="Churl-Min" last="Seong">Churl-Min Seong</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Kuo, Chih Jung" sort="Kuo, Chih Jung" uniqKey="Kuo C" first="Chih-Jung" last="Kuo">Chih-Jung Kuo</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001858 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001858 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:19166843
   |texte=   Individual and common inhibitors of coronavirus and picornavirus main proteases.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:19166843" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Individual and common inhibitors of coronavirus and picornavirus main proteases.

Individual and common inhibitors of coronavirus and picornavirus main proteases.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki